Easton Signs LOI with Licensed Medical Marijuana Grower in Canada
Ryan Allway
February 7th, 2014
News, Top Story
Easton Pharmaceuticals Inc. (OTC Pink: EAPH), a specialty pharmaceutical company that owns, designs, develops, and markets an array of topically-delivered drugs and therapeutic/cosmetic healthcare products, expressed an interest in entering the medical marijuana field in both the U.S. and Canada back in 2013. This week, the company signed a letter of intent with a private company based in British Columbia that has been approved for a medical marijuana license to grow and distribute medical marijuana throughout all of Canada. A letter of intent is a document outlining an agreement between the two parties before the agreement is finalized.
Read the full press release discussing the agreement here:
Easton Pharmaceuticals Inc. (OTC: EAPH) a specialty pharmaceutical company that owns, designs, develops, and markets an array of topically-delivered drugs and therapeutic / cosmetic healthcare products, today announces It has finalized and closed on agreement to engage a leading legal consultant on medical marijuana. Subsequent to this agreement, Easton has signed a Letter Of Intent / NDA and has entered into high level negotiations with a private company based out of British Columbia who has been approved for a medical marijuana license to grow and distribute medical marijuana throughout all of Canada.
Easton Pharmaceuticals has finalized and closed on an agreement with one of the foremost respected and knowledgeable legal experts and consulting firms in Canada towards medical marijuana. This company is to be lead project manager to draft and file an application on behalf of Easton Pharmaceuticals who will be completely responsible to be project manager and hire security firms, engineers and architects and other experts who will conform the warehouse and facilities to adhere to strict Health Canada Standards for its application.
The name and details of the legal consulting firm are being kept private for a very short period of time as a result of the company executing a letter of intent / NDA and entering into high level discussions with a British Columbia based private company who has just been approved and granted a medical marijuana license for growing and distributing throughout Canada. The introduction and the quick circumstances towards executing the letter of intent was not only unexpected, but was signed 1 day after entering into a contract with the legal consulting firm, superseding all other discussions with other companies. The B.C. private company is one of the first companies to have been approved for a license and is well respected within the industry and by health Canada. They are currently in the process of building out their facility in B.C as per their approved application with plans to apply and open other facilities to serve the greater Toronto area, North America’s 4th largest city and other eastern jurisdictions in the country, which may possibly involve Easton Pharmaceuticals. The company and management believe a fair and equitable partnership agreement can be attained, apart from some details and issues. Should negotiations not result in any agreement, the company will continue with moving on its own highly detailed medical marijuana application utilizing the knowledge and expertise of its legal consultant who are currently consulting the government of Uruguay with its own marijuana laws. Negotiations and discussions are to be very fast moving, with an expected decision to be made within the next week to 10 days, followed by a formal announcement.
About Easton Pharmaceuticals
Easton Pharmaceuticals is a specialty pharmaceutical company that owns, designs, develops, and markets topically-delivered Drugs and therapeutic healthcare products, focused on Cancer and other health issues related to male and female sexual dysfunction, wound healing, pain, motion sickness, scar and stretch marks, cellulite, varicose veins and other conditions. The company’s gel formulation is thought to be an innovative and unique transdermal delivery system. Easton Pharmaceuticals product “VIORRA,” is an over-the-counter aid for the treatment to restore and improve vaginal moisture and elasticity which is believed to have a positive effect on women’s sexual desire and arousal, FSAD (Female Sexual Arousal Disorder) the world market for these female conditions are conservatively estimated to be in excess of $2 billion. VIORRA is a topical, daily-use product classified by the FDA as containing Generally Recognized as Safe ingredients.
For More Information Visit
http://www.eastonpharma.com http://www.ashleybiomedical.com
Safe Harbor
This news release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (The “Act”). In particular, when used in the preceding of discussion, the words “pleased,” “plan,” “confident that,” “believe,” “expect,” “possible” or “intent to” and similar conditional expressions are intended to identify forward-looking statements within the meaning of the Act and are subject to the safe harbor created by the Act. Such statements are subject to certain risks and uncertainties and actual results could differ materially from those expressed in any of the forward-looking statements. Such risks and uncertainties include, but are not limited to, market conditions, general acceptance of the company’s products and technologies, competitive factors, the ability to successfully complete additional or adequate financing, government approvals or changes to proposed laws and other risks and uncertainties further stated in the company’s financial reports and filings.
This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.
Network Partners
About CFN Media Group
CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.
Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.
Copyright © Accelerize Inc. · All Rights Reserved · Privacy Policy · Legal Disclaimer